{"entity":{"id":"mt-228","kind":"drug","name":"MT-228","aka":[],"tldr":"MT-228 is an experimental small molecule from Myosin Therapeutics, in preclinical development for undisclosed cancer.","summary":"MT-228 is a small molecule from Myosin Therapeutics. A small-molecule inhibitor of non-muscle myosin IIA and IIB (the products of MYH9 and MYH10) being pursued for non-orphan oncology indications. Its furthest stage is preclinical development, for undisclosed cancer. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Myosin Therapeutics: myosintherapeutics.com","url":"https://www.myosintherapeutics.com/pipeline.php"},{"label":"Myosin Therapeutics: myosintherapeutics.com","url":"https://www.myosintherapeutics.com/pipeline.php"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["myh9"],"drugs":[],"companies":["myosin-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"MT-228","modality":"Small molecule","mechanism":"A small-molecule inhibitor of non-muscle myosin IIA and IIB (the products of MYH9 and MYH10) being pursued for non-orphan oncology indications.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mt-228/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"myh9","kind":"target","name":"MYH9","route":"/targets/myh9/"}],"company":[{"id":"myosin-therapeutics","kind":"company","name":"Myosin Therapeutics","route":"/companies/myosin-therapeutics/"}]}}